BIO-RAD LABORATORIES-A (BIO) Fundamental Analysis & Valuation

NYSE:BIO • US0905722072

Current stock price

272.12 USD
+7.12 (+2.69%)
At close:
272 USD
-0.12 (-0.04%)
After Hours:

This BIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. BIO Profitability Analysis

1.1 Basic Checks

  • In the past year BIO was profitable.
  • BIO had a positive operating cash flow in the past year.
  • In multiple years BIO reported negative net income over the last 5 years.
  • BIO had a positive operating cash flow in each of the past 5 years.
BIO Yearly Net Income VS EBIT VS OCF VS FCFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • BIO's Return On Assets of 7.18% is amongst the best of the industry. BIO outperforms 85.71% of its industry peers.
  • BIO has a Return On Equity of 10.20%. This is amongst the best in the industry. BIO outperforms 80.36% of its industry peers.
  • BIO has a Return On Invested Capital of 2.02%. This is in the better half of the industry: BIO outperforms 62.50% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 12.34%.
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROIC 2.02%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
BIO Yearly ROA, ROE, ROICBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20

1.3 Margins

  • BIO has a Profit Margin of 29.42%. This is amongst the best in the industry. BIO outperforms 98.21% of its industry peers.
  • BIO's Profit Margin has declined in the last couple of years.
  • With a decent Operating Margin value of 10.30%, BIO is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • BIO's Operating Margin has declined in the last couple of years.
  • BIO has a Gross Margin of 52.01%. This is in the better half of the industry: BIO outperforms 62.50% of its industry peers.
  • In the last couple of years the Gross Margin of BIO has declined.
Industry RankSector Rank
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
BIO Yearly Profit, Operating, Gross MarginsBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BIO Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
  • BIO has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BIO has less shares outstanding
  • The debt/assets ratio for BIO has been reduced compared to a year ago.
BIO Yearly Shares OutstandingBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
BIO Yearly Total Debt VS Total AssetsBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 3.05 indicates that BIO is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.05, BIO is doing good in the industry, outperforming 64.29% of the companies in the same industry.
  • The Debt to FCF ratio of BIO is 3.21, which is a good value as it means it would take BIO, 3.21 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.21, BIO belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
  • A Debt/Equity ratio of 0.16 indicates that BIO is not too dependend on debt financing.
  • The Debt to Equity ratio of BIO (0.16) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Altman-Z 3.05
ROIC/WACC0.19
WACC10.47%
BIO Yearly LT Debt VS Equity VS FCFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • BIO has a Current Ratio of 5.62. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
  • BIO has a better Current ratio (5.62) than 83.93% of its industry peers.
  • A Quick Ratio of 4.19 indicates that BIO has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 4.19, BIO is doing good in the industry, outperforming 78.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.62
Quick Ratio 4.19
BIO Yearly Current Assets VS Current LiabilitesBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIO Growth Analysis

3.1 Past

  • BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
  • The Earnings Per Share has been decreasing by -1.19% on average over the past years.
  • The Revenue has been growing slightly by 0.65% in the past year.
  • BIO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.29% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%

3.2 Future

  • The Earnings Per Share is expected to grow by 0.58% on average over the next years.
  • Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 2.54% on average per year.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year2.04%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIO Yearly Revenue VS EstimatesBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
BIO Yearly EPS VS EstimatesBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. BIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 27.43, which means the current valuation is very expensive for BIO.
  • Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 69.64% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.50, BIO is valued at the same level.
  • A Price/Forward Earnings ratio of 26.23 indicates a quite expensive valuation of BIO.
  • Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 67.86% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.67, BIO is valued at the same level.
Industry RankSector Rank
PE 27.43
Fwd PE 26.23
BIO Price Earnings VS Forward Price EarningsBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, BIO is valued cheaper than 82.14% of the companies in the same industry.
Industry RankSector Rank
P/FCF 19.61
EV/EBITDA N/A
BIO Per share dataBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
  • BIO has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)6
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIO Dividend Analysis

5.1 Amount

  • No dividends for BIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO Fundamentals: All Metrics, Ratios and Statistics

BIO-RAD LABORATORIES-A

NYSE:BIO (3/24/2026, 8:04:00 PM)

After market: 272 -0.12 (-0.04%)

272.12

+7.12 (+2.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners90.44%
Inst Owner Change-2.09%
Ins Owners8.17%
Ins Owner Change0%
Market Cap7.34B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target341.7 (25.57%)
Short Float %5.17%
Short Ratio3.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-5.63%
PT rev (3m)-5.63%
EPS NQ rev (1m)-6.43%
EPS NQ rev (3m)-26.33%
EPS NY rev (1m)1.2%
EPS NY rev (3m)-0.1%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE 27.43
Fwd PE 26.23
P/S 2.84
P/FCF 19.61
P/OCF 13.8
P/B 0.99
P/tB 1.1
EV/EBITDA N/A
EPS(TTM)9.92
EY3.65%
EPS(NY)10.37
Fwd EY3.81%
FCF(TTM)13.88
FCFY5.1%
OCF(TTM)19.72
OCFY7.25%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)6
PEG (5Y)N/A
Graham Number248.27
Profitability
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROCE 2.65%
ROIC 2.02%
ROICexc 2.38%
ROICexgc 2.62%
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
FCFM 14.5%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.1%
Interest Coverage -5.71
Cash Conversion N/A
Profit Quality 49.3%
Current Ratio 5.62
Quick Ratio 4.19
Altman-Z 3.05
F-Score5
WACC10.47%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year2.04%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%

BIO-RAD LABORATORIES-A / BIO Fundamental Analysis FAQ

What is the fundamental rating for BIO stock?

ChartMill assigns a fundamental rating of 5 / 10 to BIO.


Can you provide the valuation status for BIO-RAD LABORATORIES-A?

ChartMill assigns a valuation rating of 4 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Fairly Valued.


What is the profitability of BIO stock?

BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for BIO stock?

The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 4.57% in the next year.